BCL2 in Follicular Lymphoma: t(14;18), Protein Expression, and the Reactive-versus-Neoplastic Question

The Biology BCL2 Testing Captures

BCL2 is an anti-apoptotic protein — its job is to keep cells alive by blocking programmed cell death. In normal lymph node physiology, that matters enormously inside the germinal center, the anatomic engine where B cells undergo affinity maturation. Germinal-center B cells are supposed to be primed for apoptosis; those that fail to make a useful antibody die, and the ones that succeed are rescued. Because of this, reactive germinal-center B cells normally switch BCL2 off. That single physiologic fact is the diagnostic lever this whole workup turns on.

Follicular lymphoma (FL) subverts the arrangement. In the great majority of cases, the tumor carries t(14;18)(q32;q21), a translocation that juxtaposes the BCL2 gene on chromosome 18 next to the immunoglobulin heavy-chain enhancer on chromosome 14 [1,2]. The consequence is constitutive, deregulated BCL2 overexpression: the neoplastic follicular B cells refuse to die when they should. The translocation is thought to arise as an error during V(D)J recombination in early B-cell development, and it's the molecular founding event in most FL [3].

How BCL2 Is Tested in Follicular Lymphoma: IHC and FISH

Both assays here run on formalin-fixed, paraffin-embedded (FFPE) tissue — usually an excisional or core biopsy of a lymph node or extranodal site.

Immunohistochemistry (IHC) stains for BCL2 protein and is read in architectural context. The pathologist isn't scoring a percentage in isolation; the interpretive question is where the positivity lives. In FL, the neoplastic follicles light up for BCL2. In a reactive node, the germinal centers stay negative while the surrounding mantle and interfollicular T cells (which express BCL2 normally) serve as a built-in internal positive control. That contrast — BCL2-negative reactive follicle against a BCL2-positive background — is the pearl. When I'm reading a follicular proliferation, the first thing I want to see is whether the germinal centers show a clean BCL2-negative "hole" or fill in solidly.

FISH for t(14;18) uses dual-color break-apart or fusion probes to detect the BCL2/IGH rearrangement directly at the DNA level. It's the molecular confirmation when protein and morphology leave ambiguity.

Preanalytics matter. Fixation time, antigen retrieval, and antibody clone all influence BCL2 IHC intensity, and weak or equivocal staining is a real interpretive trap. FISH is more robust to these variables but depends on adequate tumor cellularity and preserved nuclei in the FFPE block.

Reading the Result States

BCL2-positive neoplastic follicles support a diagnosis of follicular lymphoma, particularly when combined with follicular architecture and germinal-center markers (CD10, BCL6). The finding argues strongly against reactive follicular hyperplasia.

t(14;18) present confirms the BCL2/IGH rearrangement, the defining lesion of classic FL.

t(14;18) absent does not exclude follicular lymphoma. This is where the two assays complement rather than duplicate each other — a t(14;18)-negative case can still be BCL2-positive by IHC through alternative mechanisms, and some genuine FL is rearrangement-negative altogether (discussed below).

What the Diagnosis Enables Clinically

Establishing follicular lymphoma versus reactive hyperplasia is not a formality — it's the fork in the road. A reactive node needs no oncologic management; a lymphoma triggers staging, grading, and an entirely different clinical pathway. BCL2 IHC and t(14;18) are the tools that separate a florid but benign immune response from an indolent B-cell malignancy that can behave very differently over years.

Because FL is a mature B-cell neoplasm that reliably expresses CD20, a confirmed diagnosis places the patient within the population eligible for anti-CD20-directed therapy classes, alongside conventional chemoimmunotherapy approaches used in low-grade B-cell lymphomas. The point of emphasis for a mixed audience: the biomarker establishes what the disease is, which in turn defines the drug classes for which a patient may be a candidate. It does not, by itself, dictate any individual's regimen.

Grade also feeds into this. FL is graded by centroblast counts, and grade 3B behaves biologically more like an aggressive lymphoma — and, importantly, grade 3B FL is frequently t(14;18)-negative and may lack strong BCL2 expression [1,3]. So a negative molecular result carries different weight depending on where a case sits on the grade spectrum.

Caveats and Evolving Areas in BCL2 / Follicular Lymphoma Diagnostics

The honest caveat is that BCL2 IHC is a supporting argument, not a verdict. BCL2 is expressed by many cell types, so positive follicles must always be interpreted with morphology and a germinal-center immunophenotype — I've seen colonization and partial involvement mimic and mask both patterns, which is exactly why FISH earns its place.

Several t(14;18)-negative FL subtypes deserve attention. A subset of FL is driven by BCL6 rearrangement rather than BCL2, and these cases can be BCL2-IHC weak or negative while remaining bona fide follicular lymphoma [1,2,3]. Pediatric-type follicular lymphoma is a distinct entity that is characteristically t(14;18)-negative and BCL2-negative, with localized disease and indolent behavior; misreading it against adult-FL expectations is a recognized pitfall [1,2]. These variants are the reason a negative t(14;18) never closes the door.

Grade 3B FL, as noted, frequently departs from the classic BCL2-positive/t(14;18)-positive profile and sits at the interface with large B-cell lymphoma [1,3]. And in the setting of histologic transformation to a more aggressive lymphoma, BCL2 and rearrangement status may be revisited on the new biopsy — both to confirm clonal relationship and to characterize the transformed disease, since acquisition of additional lesions (such as MYC) changes the biology.

The classification frameworks themselves continue to move. WHO-HAEM5 and the ICC both refined FL definitions and subtypes in 2022, and they don't align on every boundary or terminology point [1,2]. For practicing pathologists, the durable message is methodological: interpret BCL2 IHC only against internal controls and architecture, and treat FISH as the arbiter when protein and morphology disagree — because it's precisely the discordant cases, the BCL2-dim grade 3B and the rearrangement-negative variant, where a reflexive read gets the diagnosis wrong.

References

1. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the WHO Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022. doi:10.1038/s41375-022-01620-2

2. Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms. Blood. 2022. doi:10.1182/blood.2022015851

3. Louissaint A Jr, Freedman AS, Lorsbach RB. Follicular lymphoma: updates for pathologists. Modern Pathology. 2022. PMCID: PMC8743801